Does Trastuzumab Offer Good Value for Money for Breast Cancer Patients with Metastasis in Indonesia?
Erna KristinDwi EndartiLevina Chandra KhoeWoro Rukmi PratiwiRizaldy Taslim PinzonRatih Puspita FebrinasariAlfi YasminaDwi Aris Agung NugrahaningsihKartika Widayati Taroeno-HariadiRamadhan KarsonoI Wayan SudarsaMuhammad Darwin PrenggonoEva HerlinawatyKalsum KomaryaniBudi HidayatMardiati NadjibPublished in: Asian Pacific journal of cancer prevention : APJCP (2022)
In conclusion, this economic evaluation suggests that the addition of trastuzumab to standard chemotherapy is not cost-effective in terms of PFS and OS compared with chemotherapy alone.<br />.